Quaker BioVentures

Kaarta, Inc. specializes in 3D model generation software that processes environmental data to create accurate and usable 3D models. The company utilizes a patented technology rooted in advanced robotics to enable real-time mobile 3D reality capture, mapping complex environments efficiently without reliance on external signal infrastructures like GPS or Wi-Fi. Its offerings include a hand-held 3D scanning system, called Contour, which allows users to walk through an environment while generating a 3D map in real-time. Kaarta also provides Stencil 2, a mobile mapping platform designed for rapid scanning. By employing specialized localization algorithms and purpose-built technology, Kaarta enhances the ability to bridge the physical world with its digital twin, serving a variety of applications in architecture, geospatial analysis, and autonomous robotics. Founded in 2015 and headquartered in Pittsburgh, Pennsylvania, the company was previously known as Real Earth, Inc. before rebranding in December 2016.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

PreCision Dermatology is a rapidly growing company dedicated to advancing skincare through innovative therapies. It focuses on developing products that enhance the delivery of active ingredients to the skin, reducing side effects and strengthening the skin's natural barrier. The company's portfolio addresses various dermatological conditions like atopic dermatitis, acne, and rosacea. PreCision Dermatology expands its offerings through internal research, acquisitions, licensing agreements, and strategic partnerships.

RainDance Technologies, Inc. specializes in developing advanced genomic tools for non-invasive liquid biopsy applications, focusing on cancer detection, treatment, and the study of inherited and infectious diseases. The company's flagship product, the RainDrop digital polymerase chain reaction platform, utilizes picoliter-sized droplets to facilitate multiplex detection of genetic material, including DNA and RNA. Additionally, RainDance offers the RainDrop Plus digital PCR system, which integrates next-generation sequencing (NGS) amplicon enrichment with digital PCR capabilities. Their automated ThunderStorm solution enhances NGS content enrichment, allowing laboratories to process multiple samples efficiently while ensuring high-quality data. The ThunderBolts panels target critical cancer mutations and specific genetic markers associated with myeloid disorders. RainDance's products include a range of consumables designed to optimize various laboratory processes. Founded in 2004 and headquartered in Billerica, Massachusetts, the company serves research institutions and laboratories globally through a network of sales representatives and distributors. RainDance Technologies operates as a subsidiary of Bio-Rad Laboratories, Inc.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.

Tarsa Therapeutics, Inc. is a pharmaceutical company focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases in women, particularly postmenopausal osteoporosis. The company's lead product, TBRIA, is an oral formulation of salmon calcitonin, a peptide hormone designed to slow the rate of bone destruction. Tarsa Therapeutics aims to provide effective treatment options for women who are more than five years post-menopause and for whom alternative therapies may not be suitable. Founded in 2009 and based in Philadelphia, Pennsylvania, the company was previously known as Boneco, Inc.

NovaSom Inc., established in 1992 and headquartered in Glen Burnie, Maryland, specializes in home-based diagnostic services for sleep-disordered breathing conditions, notably obstructive sleep apnea (OSA). As a Medicare-approved Independent Diagnostic Testing Facility and Joint Commission-accredited provider, NovaSom offers FDA-cleared home testing systems. Their cloud-based platform facilitates collaborative patient management between physicians and payers, ensuring efficient, accurate, and comfortable evaluations for patients in their own homes.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

RainDance Technologies, Inc. specializes in developing advanced genomic tools for non-invasive liquid biopsy applications, focusing on cancer detection, treatment, and the study of inherited and infectious diseases. The company's flagship product, the RainDrop digital polymerase chain reaction platform, utilizes picoliter-sized droplets to facilitate multiplex detection of genetic material, including DNA and RNA. Additionally, RainDance offers the RainDrop Plus digital PCR system, which integrates next-generation sequencing (NGS) amplicon enrichment with digital PCR capabilities. Their automated ThunderStorm solution enhances NGS content enrichment, allowing laboratories to process multiple samples efficiently while ensuring high-quality data. The ThunderBolts panels target critical cancer mutations and specific genetic markers associated with myeloid disorders. RainDance's products include a range of consumables designed to optimize various laboratory processes. Founded in 2004 and headquartered in Billerica, Massachusetts, the company serves research institutions and laboratories globally through a network of sales representatives and distributors. RainDance Technologies operates as a subsidiary of Bio-Rad Laboratories, Inc.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Blue Bell, Pennsylvania, specializing in the discovery, development, and commercialization of small molecule drug therapies targeting immune system disorders. Its lead candidate, ACH-4471, is a factor D inhibitor currently undergoing Phase II clinical trials for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy. The company is also advancing other factor D inhibitors, including ACH-5228 and ACH-5548, both of which are in Phase I clinical trials for PNH and other complement-mediated diseases. Achillion has established license agreements with Ora, Inc. for the development of ACH-702 and with GCA Therapeutics, Ltd. for elvucitabine, a treatment for hepatitis B and HIV. Founded in 1998, Achillion operates as a subsidiary of Alexion Pharmaceuticals, Inc. Its focus is on advancing therapies that address disorders linked to the complement system, which plays a crucial role in the innate immune response.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.

Helomics Corporation is a personalized healthcare company based in Pittsburgh, Pennsylvania, focused on enhancing cancer care through a range of innovative diagnostic products and services. The company has developed the Precision Cellular Analytical Platform, which analyzes cell cycle and proliferation data over a 25-35 day period. Helomics' offerings include ChemoFx, which assists in selecting effective treatments for gynecologic cancer, and BioSpeciFx, a set of biomarker tests that provide insights into tumor characteristics and potential drug responses. Additionally, Helomics provides GeneFx Colon and GeneFx Lung, microarray-based gene signatures tailored for patients with stage two colon cancer and early-stage non-small cell lung cancer, respectively. The company also engages in tumor profiling services, including bioinformatics and contract research, to support clinical decision-making. Furthermore, Helomics utilizes its D-CHIP digital clinical health insight platform to deliver personalized oncology roadmaps and collaborates with pharmaceutical and diagnostics companies to enhance patient selection for clinical trials. Founded in 1995 and formerly known as Precision Therapeutics, Helomics continues to push the boundaries of precision oncology.

TearScience, Inc. is a medical device company based in Morrisville, North Carolina, specializing in the identification, diagnosis, and treatment of meibomian gland disease (MGD), a primary cause of dry eye affecting millions worldwide. Founded in 2005, TearScience has developed innovative devices to address evaporative dry eye, including the LipiFlow Activator, which delivers automated therapeutic energies to treat the meibomian glands, and the LipiScan, an imaging tool that allows eye care professionals to assess gland health. The company's integrated system enables effective management of MGD, which is often underestimated despite being a leading contributor to dry eye symptoms such as irritation, dryness, and visual disturbances. As a subsidiary of Johnson & Johnson Surgical Vision, TearScience continues to advance its mission of improving patient outcomes through early detection and treatment of this chronic condition.

Tarsa Therapeutics, Inc. is a pharmaceutical company focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases in women, particularly postmenopausal osteoporosis. The company's lead product, TBRIA, is an oral formulation of salmon calcitonin, a peptide hormone designed to slow the rate of bone destruction. Tarsa Therapeutics aims to provide effective treatment options for women who are more than five years post-menopause and for whom alternative therapies may not be suitable. Founded in 2009 and based in Philadelphia, Pennsylvania, the company was previously known as Boneco, Inc.

BioLeap is an innovative drug discovery company that leverages advanced computational fragment-based design technology. Its design platform predicts binding affinity based on thermodynamic principles, enabling drug designers to efficiently develop non-obvious molecules and enhance existing ones. This approach addresses the challenge of limited chemical diversity that often hampers lead identification and optimization phases in drug development. BioLeap's technology serves as a promising alternative to traditional high-throughput screening and shape-based docking methods. The company has successfully identified lead compounds through collaborative ventures and is actively seeking new partnerships to further utilize its compound design and engineering platform.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, specifically targeting antidote-controlled treatments. Founded in 2001 and headquartered in Durham, North Carolina, the company is known for its innovative approach to antithrombotic therapies, including its lead product, REG1, which is designed for patients experiencing acute coronary syndrome undergoing coronary revascularization procedures. Regado's research emphasizes the development of therapeutic aptamers paired with active control agents, aiming to address both arterial and venous thrombosis effectively.

Sleep Solutions (SSI) is a privately held diagnostic service provider specializing in the evaluation and home testing of sleep-disordered breathing, particularly Obstructive Sleep Apnea (OSA). The company offers an efficient and cost-effective alternative to traditional in-laboratory sleep studies, utilizing its proprietary sound analysis technology. Through its NovaSom QSG home-diagnostic system, Sleep Solutions delivers testing directly to patients, facilitating a more comfortable experience. In addition to diagnosis, the company provides services focused on therapy and compliance management for individuals affected by sleep-disordered breathing.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

Asensus Surgical is a medical device company focused on enhancing minimally invasive surgery through digital laparoscopy. By digitizing the interface between surgeons and patients, the company incorporates advanced technologies such as augmented intelligence, connectivity, and robotics into surgical procedures. Their flagship product, the Senhance Surgical System, is notable for being the first machine vision system designed for robotic surgery. This system is supported by the Intelligent Surgical Unit, which facilitates augmented intelligence in surgery. Asensus Surgical aims to address various clinical, cognitive, and economic challenges faced in surgical practices, ultimately improving patient outcomes through innovative solutions in digital laparoscopy.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

Helomics Corporation is a personalized healthcare company based in Pittsburgh, Pennsylvania, focused on enhancing cancer care through a range of innovative diagnostic products and services. The company has developed the Precision Cellular Analytical Platform, which analyzes cell cycle and proliferation data over a 25-35 day period. Helomics' offerings include ChemoFx, which assists in selecting effective treatments for gynecologic cancer, and BioSpeciFx, a set of biomarker tests that provide insights into tumor characteristics and potential drug responses. Additionally, Helomics provides GeneFx Colon and GeneFx Lung, microarray-based gene signatures tailored for patients with stage two colon cancer and early-stage non-small cell lung cancer, respectively. The company also engages in tumor profiling services, including bioinformatics and contract research, to support clinical decision-making. Furthermore, Helomics utilizes its D-CHIP digital clinical health insight platform to deliver personalized oncology roadmaps and collaborates with pharmaceutical and diagnostics companies to enhance patient selection for clinical trials. Founded in 1995 and formerly known as Precision Therapeutics, Helomics continues to push the boundaries of precision oncology.

Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.

Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

NuPathe Inc., a Pennsylvania-based specialty pharmaceutical company, specializes in developing and commercializing branded therapeutics for neurological and psychiatric disorders. Its primary product, Zecuity, is a transdermal patch used for acute migraine treatment. NuPathe's pipeline includes NP201, a long-acting treatment for Parkinson's disease, and NP202, a long-term solution for schizophrenia and bipolar disorder, both leveraging its biodegradable implant technology. The company, founded in 2005, operates as a subsidiary of Teva Pharmaceutical Industries Limited and is actively seeking partnerships to expand its global reach.

Diasome Pharmaceuticals, Inc. is a clinical stage diabetes therapeutics company focused on designing and developing innovative insulin-based therapies for the treatment of Type 1 and Type 2 diabetes. Founded in 2004, the company is headquartered in Cleveland, Ohio. Diasome's flagship product, the hepatocyte directed vesicle (HDV), is a nanoscale carrier that delivers multiple insulin molecules directly to the liver and is compatible with all commercially available insulin delivery methods, including insulin pumps. The company also offers Oral HVD-I, a targeted oral insulin in pill or gel cap form, and injectable insulin options such as HDV-I, a short-acting formulation, and HDV-B, a long-acting formulation. Through its proprietary technology, Diasome aims to improve glycemic control and optimize insulin delivery systems for diabetes patients.

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

EKR Therapeutics, Inc. is a specialty pharmaceutical company based in Bedminster, New Jersey, established in 2005. The company is dedicated to acquiring, developing, and commercializing prescription products specifically tailored for oncology supportive care and various acute-care hospital needs. EKR Therapeutics focuses on addressing a range of medical issues, including oral mucositis, stomatitis, dry mouth, nutritional challenges, cachexia, skin reactions, bone marrow depression, bone complications, pain management, nausea, vomiting, and diarrhea. By providing effective treatment options, EKR Therapeutics aims to enhance the quality of life for cancer patients and those experiencing acute medical conditions.

Tranzyme Pharma is a biopharmaceutical company based in North Carolina, specializing in the discovery, development, and commercialization of mechanism-based therapies for gastrointestinal motility disorders. The company focuses on small molecule therapeutics to address both acute and chronic conditions. Its product portfolio includes TZP-101, designed for the treatment of post-operative ileus and severe gastroparesis, and TZP-301, aimed at addressing obesity and metabolic syndrome. Tranzyme Pharma retains worldwide rights for its therapeutic programs, underscoring its commitment to advancing treatment options in the field of gastrointestinal health.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

Optherion, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2005. The company specializes in the development of diagnostic tools and disease-modifying therapeutics aimed at managing and treating early-stage age-related macular degeneration, dense deposit disease, atypical hemolytic uremic syndrome, and other chronic diseases related to the alternative complement cascade. Through its innovative approaches, Optherion seeks to address significant medical needs in the field of ophthalmology and related disorders.

EKR Therapeutics, Inc. is a specialty pharmaceutical company based in Bedminster, New Jersey, established in 2005. The company is dedicated to acquiring, developing, and commercializing prescription products specifically tailored for oncology supportive care and various acute-care hospital needs. EKR Therapeutics focuses on addressing a range of medical issues, including oral mucositis, stomatitis, dry mouth, nutritional challenges, cachexia, skin reactions, bone marrow depression, bone complications, pain management, nausea, vomiting, and diarrhea. By providing effective treatment options, EKR Therapeutics aims to enhance the quality of life for cancer patients and those experiencing acute medical conditions.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Argolyn Bioscience is a biotechnology company that develops peptide drug candidates to treat serious diseases and disorders. The company’s products are based on amino acid analog substitution technology. The company's products include ABS201 for schizophrenia and ABS212 for pain.

Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.

StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

Regado Biosciences is a biopharmaceutical company focused on the discovery and development of aptamer-based therapeutics, specifically targeting antidote-controlled treatments. Founded in 2001 and headquartered in Durham, North Carolina, the company is known for its innovative approach to antithrombotic therapies, including its lead product, REG1, which is designed for patients experiencing acute coronary syndrome undergoing coronary revascularization procedures. Regado's research emphasizes the development of therapeutic aptamers paired with active control agents, aiming to address both arterial and venous thrombosis effectively.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on the discovery and development of small molecule drugs that target programmed cell death pathways to address serious diseases. The company's lead products, known as Smac Mimetics, work by neutralizing key inhibitors in the apoptosis pathway, allowing for the selective destruction of cancer cells. Additionally, TetraLogic develops Necrostatin drugs, which inhibit critical processes leading to necrosis, thus promoting cell survival in various conditions where necrosis plays a significant role in disease progression. Through these innovative therapeutic approaches, TetraLogic aims to improve treatment outcomes in oncology and other medical fields.

NitricBio is a mid-stage specialty pharmaceutical company focused on the dermatology and podiatry markets, with two unique drug delivery technologies. The first technology involves the development and commercialization of topical nitric oxide gas. Nitric oxide has both direct and regulatory actions with known anti-infective and anti-inflammatory properties. The company's current focus is on the development of a treatment for moderate-to-severe tinea pedis (athlete's foot), which is currently in late Phase 2 clinical trials.

Helomics Corporation is a personalized healthcare company based in Pittsburgh, Pennsylvania, focused on enhancing cancer care through a range of innovative diagnostic products and services. The company has developed the Precision Cellular Analytical Platform, which analyzes cell cycle and proliferation data over a 25-35 day period. Helomics' offerings include ChemoFx, which assists in selecting effective treatments for gynecologic cancer, and BioSpeciFx, a set of biomarker tests that provide insights into tumor characteristics and potential drug responses. Additionally, Helomics provides GeneFx Colon and GeneFx Lung, microarray-based gene signatures tailored for patients with stage two colon cancer and early-stage non-small cell lung cancer, respectively. The company also engages in tumor profiling services, including bioinformatics and contract research, to support clinical decision-making. Furthermore, Helomics utilizes its D-CHIP digital clinical health insight platform to deliver personalized oncology roadmaps and collaborates with pharmaceutical and diagnostics companies to enhance patient selection for clinical trials. Founded in 1995 and formerly known as Precision Therapeutics, Helomics continues to push the boundaries of precision oncology.

Precision Therapeutics is a pharmaceutical research and development business that develops personalized cancer treatments for patients.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Tranzyme Pharma is a biopharmaceutical company based in North Carolina, specializing in the discovery, development, and commercialization of mechanism-based therapies for gastrointestinal motility disorders. The company focuses on small molecule therapeutics to address both acute and chronic conditions. Its product portfolio includes TZP-101, designed for the treatment of post-operative ileus and severe gastroparesis, and TZP-301, aimed at addressing obesity and metabolic syndrome. Tranzyme Pharma retains worldwide rights for its therapeutic programs, underscoring its commitment to advancing treatment options in the field of gastrointestinal health.

TargetRx is a provider of insights focused on the pharmaceutical and biotech sectors, offering valuable understanding of the factors influencing product choice and adoption among healthcare professionals. The company specializes in analyzing physician behavior to assist pharmaceutical companies in making informed decisions regarding forecasting, product positioning, and promotional strategies for new drug launches. TargetRx's comprehensive suite of services extends from the early stages of product development through to patent expiration, enabling clients to optimize their marketing messages and campaign materials effectively. By delivering actionable insights, TargetRx supports its clients in enhancing their business growth while ultimately benefiting patient care.

Neotropix, Inc. is a biotechnology company based in Malvern, Pennsylvania, established in 2003. The company specializes in the development and commercialization of systemically deliverable oncolytic viruses aimed at treating neuroendocrine cancers. Its primary product, NTX010, is a naturally-occurring virus designed to target and eliminate neuroendocrine tumors, including small cell lung cancer, carcinoid, neuroblastoma, and various small cell carcinomas originating in other organs. Through its innovative approach, Neotropix seeks to provide effective therapeutic options for medical practitioners dealing with challenging cancer types.

Nucleonics is a biotechnology company focused on RNA interference-based therapeutics.

MedMark Services, Inc. is a healthcare provider specializing in addiction treatment and primary healthcare services in the United States, with a focus on opioid addiction and dependency for adults. Founded in 1998 and headquartered in Lewisville, Texas, MedMark offers a range of outpatient services, including medication-assisted treatment using methadone and buprenorphine, as well as primary care services that encompass chronic illness management, preventive healthcare screenings, nutritional consultations, and outpatient nursing care. Additional offerings include mental health assessments, social services referrals, phlebotomy, and telehealth services. MedMark operates multiple outpatient locations across several states, including Alabama, California, Florida, Georgia, Maryland, and Texas, and functions as a subsidiary of Addiction Research and Treatment, Inc.

BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.

Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.

BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.